Literature DB >> 10556576

Suppression of macrophage responses to bacterial lipopolysaccharide by a non-secretory form of secretory leukocyte protease inhibitor.

J Zhu1, C Nathan, A Ding.   

Abstract

Expression of secretory leukocyte protease inhibitor (SLPI) suppresses the ability of macrophages to respond to bacterial lipopolysaccharide (LPS). Here, addition of recombinant or native SLPI to the extracellular medium was non-suppressive, while transfection with a non-secretory form of SLPI was fully suppressive, an effect overcome by treatment with interferon-gamma. A portion of the SLPI produced by untransfected macrophages was localized in the cytosol. Thus, SLPI can act intracellularly to block macrophage activation by LPS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10556576     DOI: 10.1016/s0167-4889(99)00111-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

Review 1.  Antimicrobial polypeptides in host defense of the respiratory tract.

Authors:  Tomas Ganz
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

2.  Induction of macrophage-derived SLPI by Mycobacterium tuberculosis depends on TLR2 but not MyD88.

Authors:  Aihao Ding; Hongwei Yu; Jingxuan Yang; Shuangping Shi; Sabine Ehrt
Journal:  Immunology       Date:  2005-11       Impact factor: 7.397

Review 3.  The mouth: a gateway or a trap for HIV?

Authors:  Daniel Malamud; Sharon M Wahl
Journal:  AIDS       Date:  2010-01-02       Impact factor: 4.177

4.  The role of innate immunity in the pathogenesis of chronic rhinosinusitis.

Authors:  Andrew P Lane
Journal:  Curr Allergy Asthma Rep       Date:  2009-05       Impact factor: 4.806

5.  Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice.

Authors:  Akira Nakamura; Yuriko Mori; Koichi Hagiwara; Takuji Suzuki; Tomohiro Sakakibara; Toshiaki Kikuchi; Takayuki Igarashi; Masahito Ebina; Tatsuya Abe; Junichi Miyazaki; Toshiyuki Takai; Toshihiro Nukiwa
Journal:  J Exp Med       Date:  2003-03-03       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.